Climb Bio, Inc. (Nasdaq: CLYM) announced it will present clinical data for its CLYM116 and budoprutug programs at the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE